title: Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.
abstract: Graft rejection is a serious complication in cord blood transplantation (CBT), but little is known about the mechanism of rejection. To investigate the potential role of T lymphocytes in graft rejection, we isolated a CD8(+) cytotoxic T lymphocyte (CTL) clone of recipient origin from blood obtained from a patient with graft rejection after CBT from an HLA-mismatched unrelated donor. The isolated CTL clone specifically recognized an HLA-B( *)1501 molecule as an alloantigen, which was expressed in donor cells but not in recipient cells. The results of a microchimerism analysis specific for HLA-B( *)1501 and a polymerase chain reaction assay specific for the T cell receptor on DNA from pretransplant peripheral blood mononuclear cells revealed that the patient was exposed to HLA-B( *)1501 prior to CBT, and that the CTL clone was in the patient's blood prior to transplantation. The present study demonstrates a potential role for pretransplant CTL in graft rejection following CBT.
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Makoto
authors.initials: M
authors.lastname: Murata
authors.forename: Seitaro
authors.initials: S
authors.lastname: Terakura
authors.forename: Kyoko
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
mesh_terms: D002999:Clone Cells; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D018274:Electroporation; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D059811:HLA-DRB1 Chains; D006650:Histocompatibility Testing; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000276:immunology / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection; D018183:Transplantation Chimera; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D011948:Receptors, Antigen, T-Cell; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan